Abstract: Malignant tumor therapy has entered a new era of "precise treatment." Nowadays, targeted anti- angiogenic agents have become a popular research topic that continues to attract increasing interest. Tumor immune escape plays an indispensable role in therapeutic resistance. Anti-angiogenic therapies not only prevent the tumor angiogenesis and suppress tumor growth but also neu -tralize tumor escape from a host's immune system by reducing the immunosuppressive cells and increasing the number of tumor-infil -trating lymphocyte (TIL) and cytotoxic lymphocte (CTL). This paper aims to review the mechanism underlying the manner by which an -ti-angiogenesis enhances immunity by influencing tumor microenvironment.